Stereotaxis, Inc. (STXS)

In the past six months, Stereotaxis received FDA approval for its GenesisX surgical robotic system and MAGiC catheter, which likely had a positive impact on the stock. The company announced its Q3 2025 earnings, reporting that recurring revenue reflected summer seasonality in procedure volumes but was counteracted by positive momentum from Map-iT and early launches of MAGiC and MAGiC Sweep. Stereotaxis launched a new robotic electrophysiology program in Germany. The company reported its Q4 and full-year 2025 financial results, with Q4 revenue falling short of estimates but highlighting significant regulatory approvals and over 20% revenue growth for the full year 2025. The stock has experienced volatility, with its 52-week range between $1.54 and $3.59.

Stereotaxis, Inc. experiences demand seasonality for its products and services. The company's recurring revenue is impacted by summer seasonality in procedure volumes, suggesting that procedure volumes may be lower during the summer months.

Stereotaxis, Inc. is a medical technology company specializing in surgical robotics for minimally invasive endovascular interventions. It operates in the Healthcare sector, specifically in the Medical Equipment & Supplies industry. The company's core technology, Robotic Magnetic Navigation (RMN), uses computer-controlled magnetic fields to precisely guide interventional devices. Major products and technologies include the Genesis RMN System, GenesisX RMN System, Odyssey Solution, MAGiC Magnetic Interventional Ablation Catheter, MAGiC Sweep™, EMAGIN, and Niobe Magnetic Navigation System. The company's business model combines capital robotic systems, disposable devices, and digital and information solutions.

Stereotaxis' technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and other regions. The company has installations and procedures at hospitals in these areas. Stereotaxis also has a presence in China, with regulatory approvals for its Genesis system and Magbot. The company employs over 130 professionals in ten countries globally.

In the past year, Stereotaxis' brand reputation appears to be positively influenced by its focus on innovation and successful regulatory milestones. The company has consistently announced significant regulatory approvals for its next-generation robotic systems and catheters in both the United States and Europe. The launch of new robotic electrophysiology programs, such as in Germany in February 2026, also contributes to a positive perception of the company's progress and adoption of its technology. There were no explicitly negative events affecting Stereotaxis, Inc.'s reputation mentioned in the past year.

Stereotaxis, Inc. has a significant portion of its shares held by institutional and individual owners. As of March 20, 2026, there were 119 institutional owners holding a total of 41,918,561 shares. Major institutional owners include DAFNA Capital Management LLC, Lagoda Investment Management, L.P., BlackRock, Inc., Vanguard Group Inc, Arbiter Partners Capital Management LLC, Geode Capital Management, Llc, Essex Investment Management Co Llc, Warberg Asset Management LLC, Prescott Group Capital Management, L.l.c., and State Street Corp. Significant individual owners (insiders) include Nathan Fischel, Joe E. Kiani, Paul J. Isaac, and Fred A. Middleton. Institutional ownership accounts for approximately 59.35% of the company, while individuals hold about 13.67%.